Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | APOBEC3A | P31941 | 3/20 | 0.59 |
| ▸ | APOBEC3G | Q9HC16 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | BCHE | P06276 | 3/20 | 0.44 |
| ▸ | GLA | P06280 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trigonelline SCHEMBL29581532 | 1.00 | NNMT (0.68) | NNMTUSP2APOBEC3AAPOBEC3GMEN1 | |
| Trigonelline SCHEMBL5310723 | 0.98 | NNMT (0.66) | NNMTUSP2APOBEC3AAPOBEC3GMEN1 | |
| Trigonelline SCHEMBL5013564 | 0.98 | NNMT (0.66) | NNMTUSP2APOBEC3AAPOBEC3GMEN1 | |
| Trigonelline SCHEMBL15361649 | 0.98 | NNMT (0.66) | NNMTUSP2APOBEC3AAPOBEC3GMEN1 | |
| Trigonelline SCHEMBL26615275 | 0.94 | NNMT (0.61) | NNMTUSP2APOBEC3AAPOBEC3GMEN1 | |
| Trigonelline SCHEMBL11786615 | 0.86 | USP2 (0.57) | NNMTUSP2APOBEC3AAPOBEC3GMEN1 | |
| Trigonelline SCHEMBL8016829 | 0.83 | USP2 (0.58) | NNMTUSP2APOBEC3AAPOBEC3GMEN1 | |
| SCHEMBL10256967 | 0.83 | NNMT (0.63) | NNMTUSP2APOBEC3AAPOBEC3GMEN1 | |
| SCHEMBL700182 | 0.83 | NNMT (0.68) | NNMTUSP2APOBEC3AAPOBEC3GMEN1 | |
| Trigonelline SCHEMBL11771367 | 0.82 | USP2 (0.53) | NNMTUSP2APOBEC3AAPOBEC3GMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120195298-A | Metabolic marker composition for discriminating tobacco grades, screening method and application | 哈尔滨脉图精准技术有限公司 | 2025-06-24 | — | — | CN | claimed |
| CN-113490489-A | Monomethyl fumarate-carrier conjugates and methods of use thereof | 旗舰创业创新五公司 | 2021-10-08 | — | — | CN | claimed |
| CN-111593378-A | Preparation of high corrosion-resistant alkaline zinc-nickel alloy electroplating solution and components of additive | 常州新纪元材料科技有限公司 | 2020-08-28 | — | — | CN | claimed |
| EP-3630106-A1 | COMPOUNDS FOR USE IN REGULATING FOLLICLE MATURATION | Aarhus Universitet (DK) | 2020-04-08 | — | — | EP | claimed |
| CN-106661735-B | Palladium plating solution and palladium coating film obtained using the same | 日本高纯度化学株式会社 | 2019-12-10 | — | — | CN | claimed |
| WO-2018220126-A1 | COMPOUNDS FOR USE IN REGULATING FOLLICLE MATURATION | AARHUS UNIVERSITET (DK) | 2018-12-06 | — | — | WO | claimed |
| US-20090209508-A1 | Compounds for Photochemotherapy | UNIVERSITE DE GENEVE (CH) | 2009-08-20 | — | — | US | claimed |
| EP-1888115-A2 | COMPOUNDS FOR PHOTOCHEMOTHERAPY | UNIVERSITE DE GENEVE (CH) | 2008-02-20 | — | — | EP | claimed |
| WO-2007023398-A2 | COMPOUNDS FOR PHOTOCHEMOTHERAPY | UNIVERSITE DE GENEVE (US) | 2007-03-01 | — | — | WO | claimed |
| US-4332792-A | Insect attractant | ZOECON CORPORATION (US) | 1982-06-01 | — | — | US | claimed |
| JP-5194113-A | — | — | None | — | — | JP | disclosed |
| EP-4734992-A1 | METHODS AND COMPOSITIONS COMPRISING TRIGONELLINE FOR TREATING MUSCLE DECLINE AND A KIDNEY DYSFUNCTION | Société des Produits Nestlé S.A. (CH) | 2026-05-06 | — | — | EP | disclosed |
| US-12551472-B2 | Compositions and methods using trigonelline to produce intracellular nicotinamide adenine dinucleotide (NAD+) for treating or preventing physiological disorders or states | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-02-17 | — | — | US | disclosed |
| US-12491217-B2 | Compositions and methods for promoting healthy neural development in an unborn baby | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250262144-A1 | Deodorant | Java Beard, LLC | 2025-08-21 | — | — | US | disclosed |
| US-4540564-A | DIHYDROPYRIDINE AND/OR PYRIDINIUM SALT REDOX CARRIER | UNIVERSITY OF FLORIDA (US) | 1985-09-10 | — | — | US | disclosed |
| EP-0110955-A1 | BRAIN-SPECIFIC DRUG DELIVERY. | UNIV FLORIDA (US) | 1984-06-20 | — | — | EP | disclosed |
| WO-1983003968-A1 | BRAIN-SPECIFIC DRUG DELIVERY | UNIVERSITY OF FLORIDA (US) | 1983-11-24 | — | — | WO | disclosed |
| US-4332792-A | Insect attractant | ZOECON CORPORATION (US) | 1982-06-01 | — | — | US | disclosed |
| US-4332792-A | Insect attractant | ZOECON CORPORATION (US) | 1982-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551472-B2 | Compositions and methods using trigonelline to produce intracellular nicotinamide adenine dinucleotide (NAD+) for treating or preventing physiological disorders or states | NLN, NADK, GLS | NNMT 74/4885USP2 4688/4885APOBEC3A 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.